Cancer Epidemiology Biomarkers & Prevention最新文献

{"title":"Cancer Incidence in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) - The Onco-SOL Ancillary Study.","authors":"Humberto Parada, Ilir Agalliu, Daniela Sotres-Alvarez, Andrew F Olshan, Kelly R Evenson, Thomas E Rohan, Robert C Kaplan, Caroline A Thompson, Linda C Gallo, Frank J Penedo, Jianwen Cai, Sylvia Wassertheil-Smoller, Bharat Thyagarajan, Stefani N Thomas, Olga L Garcia-Bedoya, Martha L Daviglus, Gregory A Talavera","doi":"10.1158/1055-9965.EPI-24-1325","DOIUrl":"10.1158/1055-9965.EPI-24-1325","url":null,"abstract":"<p><strong>Background: </strong>Few studies have examined how cancer incidence varies by country of origin among United States Hispanic/Latino adults. Herein, we describe the incidence rates of cancer overall and for screen-detectable, tobacco-related, and obesity-related cancers among 16,415 participants in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), an ongoing population-based cohort study of Hispanic/Latino adults from diverse backgrounds.</p><p><strong>Methods: </strong>Cohort participant records were linked to the state cancer registries in New York, Florida, California, and Illinois to ascertain cancer incidence from baseline (2008-2011) through 2021. We estimated weighted age-adjusted incidence rates (IRs), and age- and sex-adjusted hazard ratios (HRs).</p><p><strong>Results: </strong>Over a mean follow-up of 10.7 (SD=2.0) years, 715 incident invasive cancers were diagnosed including 118 female breast, 102 prostate, and 79 bronchus and lung cancers. The IR of all cancers combined was 26.2 [95% confidence interval (CI)=22.6-30.2] per 10,000 (10K) person-years (py). The IRs were lowest among persons of Mexican descent [IR=19.0 (95%CI=15.0-24.1) per 10K-py] and highest for those of Puerto Rican [IR=36.6 (95%CI=28.4-47.0) per 10K-py] descent. Compared to those of Mexican descent, those of Puerto Rican, Cuban, and Dominican descent had higher hazards of cancer incidence; the incidence of obesity-related (HR=2.37; 95%CI=1.43-3.95) and tobacco-related (HR=3.00; 95%CI=1.58-5.71) cancers were also the highest among Puerto Ricans.</p><p><strong>Conclusions: </strong>Cancer incidence rates varied by Hispanic/Latino heritage and were masked when Hispanics/Latinos were aggregated into a single group.</p><p><strong>Impact: </strong>Understanding disparities in cancer risk by Hispanic/Latino heritage may help tailor cancer prevention and control strategies.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin and insulin-like growth factor and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis.","authors":"Frances Em Albers, Christopher Tv Swain, Makayla Wc Lou, S Ghazaleh Dashti, Sabina Rinaldi, Vivian Viallon, Amalia Karahalios, Kristy A Brown, Marc J Gunter, Roger L Milne, Dallas R English, Brigid M Lynch","doi":"10.1158/1055-9965.EPI-24-1304","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1304","url":null,"abstract":"<p><strong>Background: </strong>Higher concentration of insulin-like growth factor-1 (IGF-1) increases postmenopausal breast cancer risk, but evidence for insulin and c-peptide is limited. Further, not all studies have accounted for potential confounding by biomarkers from other biological pathways, and not all were restricted to estrogen receptor (ER)-positive breast cancer.</p><p><strong>Methods: </strong>This was a case-cohort study of 1,223 postmenopausal women (347 with ER-positive breast cancer) from the Melbourne Collaborative Cohort Study. We measured insulin, c-peptide, IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), and biomarkers of inflammatory and sex-steroid hormone pathways. Poisson regression with a robust variance estimator was used to estimate risk ratios (RRs) and 95% confidence intervals (95% CIs) for ER-positive breast cancer per doubling plasma concentration and for quartiles, without and with adjustment for other, potentially confounding biomarkers.</p><p><strong>Results: </strong>ER-positive breast cancer risk was not associated with doubling of insulin (RR = 0.97, 95% CI: 0.82, 1.14) or c-peptide (RR = 1.01, 95% CI: 0.80, 1.26). Risk appeared to decrease with doubling IGF-1 (RR = 0.80, 95% CI: 0.62, 1.03) and IGFBP-3 (RR = 0.62, 95% CI: 0.41, 0.90). RRs were not meaningfully different when exposures were modelled as quartiles. RRs were less than unity but imprecise after adjustment for inflammatory and sex-steroid hormone biomarkers.</p><p><strong>Conclusions: </strong>Circulating insulin, c-peptide, and IGF-1 were not positively associated with risk of ER-positive breast cancer in this case-cohort analysis of postmenopausal women.</p><p><strong>Impact: </strong>Associations between insulin and c-peptide and risk of ER-positive breast cancer in postmenopausal women are likely to be weak.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal Hematopoiesis of Indeterminant Potential as a Predictor of Colorectal Cancer Risk: Insights from the UK Biobank Cohort.","authors":"Yongfeng Liu, Zhihui Xi, Jianlong Zhou, Fa Ling, Yucheng Zhang, Huajie Xie, Jiabin Zheng, Baijin Xia, Huolun Feng, Yong Li","doi":"10.1158/1055-9965.EPI-24-1342","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1342","url":null,"abstract":"<p><strong>Background: </strong>Clonal hematopoiesis of indeterminate potential (CHIP) has been shown to be associated with the occurrence of solid tumors, but its relationship with colorectal cancer still needs to be studied.</p><p><strong>Methods: </strong>We conducted a prospective matched case-control study using data from the UK Biobank, including 5,310 incident colorectal cancer (CRC) cases and 26,550 controls matched for age, sex, and body mass index (BMI).</p><p><strong>Results: </strong>Analysis of the UK Biobank data revealed that the presence of CHIP was associated with an increased risk of CRC. The odds ratio (OR) for CRC in the presence of CHIP was 1.20 (P = 0.006). This association remained significant even after excluding participants with a family history of bowel cancer (multivariate OR, 1.19, P = 0.007). Subgroup analyses demonstrated that CHIP independently increased the risk of CRC in females (multivariate OR, 1.25, P = 0.018) and in individuals older than 60 years (multivariate OR, 1.17; P=0.046). Gene-specific analyses revealed that mutations in TET2 and ATM were particularly significant in relation to CRC risk, with OR of 1.62 (P = 0.002) for TET2 and 2.98 (P < 0.001) for ATM.</p><p><strong>Conclusions: </strong>Our findings indicate that CHIP is associated with an increased risk of CRC, particularly in individuals over 60 years of age or in females.</p><p><strong>Impact: </strong>Screening for CHIP in the population may improve the early detection and diagnosis rates of CRC.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-2014).","authors":"Yu-Ching Cheng, Carolyn M Reyes-Guzman, Carol H Christensen, Brian L Rostron, Kathryn C Edwards, Lanqing Wang, Jun Feng, Jeffery M Jarrett, Cynthia D Ward, Baoyun Xia, Heather L Kimmel, Kevin Conway, Carmine Leggett, Kristie Taylor, Charlie Lawrence, Ray Niaura, Mark J Travers, Andrew Hyland, Stephen S Hecht, Dorothy K Hatsukami, Maciej L Goniewicz, Nicolette Borek, Benjamin C Blount, Dana M van Bemmel","doi":"10.1158/1055-9965.EPI-24-1669","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1669","url":null,"abstract":"","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"34 1","pages":"209"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Urinary Cotinine and Cotinine + Trans-3'-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013-2014).","authors":"Kathryn C Edwards, Tasmia Naz, Cassandra A Stanton, Maciej L Goniewicz, Dorothy K Hatsukami, Danielle M Smith, Lanqing Wang, Andrea Villanti, Jennifer Pearson, Benjamin C Blount, Maansi Bansal-Travers, June Feng, Raymond Niaura, Michelle T Bover Manderski, Connie S Sosnoff, Cristine D Delnevo, Kara Duffy, Arseima Y Del Valle-Pinero, Brian L Rostron, Colm Everard, Heather L Kimmel, Dana M van Bemmel, Andrew Hyland","doi":"10.1158/1055-9965.EPI-24-1668","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1668","url":null,"abstract":"","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"34 1","pages":"208"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among \"All of Us\" Cancer Survivors.","authors":"Angel Arizpe, Tiffany M Chapman, Claudia Rodriguez, Alberto Carvajal, Katelyn J Queen, Stephanie Navarro, Carol Y Ochoa-Dominguez, Sue E Kim, Claudia M Toledo-Corral, Albert J Farias","doi":"10.1158/1055-9965.EPI-24-1241","DOIUrl":"10.1158/1055-9965.EPI-24-1241","url":null,"abstract":"<p><strong>Background: </strong>Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex.</p><p><strong>Methods: </strong>Cross-sectional data were extracted from adult cancer survivors in the \"All of Us\" from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors.</p><p><strong>Results: </strong>In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14-2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences.</p><p><strong>Conclusions: </strong>Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities.</p><p><strong>Impact: </strong>The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"51-58"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Cancer Risk among Immigrants and Socioeconomic Groups in the Netherlands.","authors":"Duco T Mülder, Hilliene J van de Schootbrugge-Vandermeer, James F O'Mahony, Dianqin Sun, Weiran Han, Rob H A Verhoeven, Marlon van Loo, Wessel van de Veerdonk, Manon C W Spaander, Iris Lansdorp-Vogelaar","doi":"10.1158/1055-9965.EPI-24-0889","DOIUrl":"10.1158/1055-9965.EPI-24-0889","url":null,"abstract":"<p><strong>Background: </strong>Identification of groups at a high risk of gastric cancer could facilitate targeted screening in countries with a low gastric cancer incidence. Our aim was to identify such high-risk groups based on individual-level population data on migration history and socioeconomic status (SES) in the Netherlands.</p><p><strong>Methods: </strong>In this retrospective cohort study, patient data from the Netherlands Cancer Registry were linked to demographic data of Statistics Netherlands in the period 2010 to 2022. Gastric cancer incidence rates in the 14 largest immigrant populations were compared with those born in the Netherlands. Odds ratios (OR) were computed per birthplace and controlled for age, sex, and SES. Additionally, we investigated gastric cancer risk among second-generation immigrants and by SES.</p><p><strong>Results: </strong>Immigrant populations at a significantly higher gastric cancer risk compared with the general population were identified. Specifically, foreign-born first-generation immigrants from Bosnia-Herzegovina (OR, 2.42), Turkey (OR, 2.22), and China (OR, 1.92) showed elevated risk. Whereas low SES increased the odds of developing gastric cancer, first-generation immigrants remained at higher risk even after controlling for SES. Second-generation immigrants did not have a significantly higher risk of developing gastric cancer.</p><p><strong>Conclusions: </strong>Certain first-generation immigrants remain at an elevated risk for gastric cancer despite migration to a low-risk region. Identification of these high-risk groups should be used to facilitate targeted gastric cancer prevention.</p><p><strong>Impact: </strong>Potential benefits of targeted Helicobacter pylori test-and-treat policy in immigrant populations should be explored in clinical and modeling studies. Primary care physicians should be cognizant of high-risk groups, facilitating the early detection of cancer within these populations.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"85-92"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers Suitable for Early Detection of Intrathoracic Cancers in Primary Care: A Systematic Review.","authors":"Wasim Hamad, Bogdan Grigore, Hugo Walford, Jaime Peters, Panos Alexandris, Stefanie Bonfield, Laura Standen, Rachel Boscott, Dawnya Behiyat, Isla Kuhn, Richard D Neal, Fiona M Walter, Natalia Calanzani","doi":"10.1158/1055-9965.EPI-24-0713","DOIUrl":"10.1158/1055-9965.EPI-24-0713","url":null,"abstract":"<p><p>Intrathoracic cancers, including lung cancer, mesothelioma, and thymoma, present diagnostic challenges in primary care. Biomarkers could resolve some challenges. We synthesized evidence on biomarker performance for intrathoracic cancer detection in low-prevalence settings. A search in Embase and MEDLINE included studies that recruited participants with suspected intrathoracic cancer and reported on at least one diagnostic measure for a validated, noninvasive biomarker. Studies were excluded if participants were recruited based on a preestablished diagnosis. A total of 52 studies were included, reporting on 108 individual biomarkers and panels. Carcinoembryonic antigen, CYFRA 21-1, and VEGF were evaluated for lung cancer and mesothelioma. For lung cancer, carcinoembryonic antigen and CYFRA 21-1 were the most studied, with AUCs of 0.48 to -0.90 and 0.48 to -0.83, respectively. Pro-gastrin-releasing peptide (Pro-GRP) and neuron-specific enolase (NSE) had the highest negative predictive values (NPV) (98.2% and 96.9%, respectively), whereas Early Cancer Detection Test - Lung (Early CDT) and miRNA signature classifier panels showed NPVs of 99.3% and 99.0%, respectively, in smokers. For mesothelioma, fibrillin-3 and mesothelin plus osteopontin had AUCs of 0.93 and 0.91, respectively. Thymoma panels (binding AcHR + StrAb and binding AcHR + modulating AcHR + StrAb) had 100% NPVs in patients with myasthenia gravis. The review highlights the performance of some biomarkers. However, few were evaluated in low-prevalence settings. Further evaluation is necessary before implementing these biomarkers for intrathoracic cancers in primary care.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"19-34"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hispanic/Latino Ethnicity Is an Independent Predictor of Worse Survival for Gastric Cancer in a Multicenter Safety-Net Patient Population.","authors":"Kyle D Klingbeil, Dustin L Dillon, Erfan Zarrinkhoo, Kirollos Bechay, Joon Y Park, Jordan M Rook, Michael A Mederos, Mark D Girgis, Keren Chen, Kuan-Ting Chen, Roshan Bastani, Shawdi Manouchehr-Pour, Priyanka Dubé, Karoly Viragh, Mariam Thomas, Victor Chiu, Brian E Kadera","doi":"10.1158/1055-9965.EPI-23-1224","DOIUrl":"10.1158/1055-9965.EPI-23-1224","url":null,"abstract":"<p><strong>Background: </strong>Various population-based studies have shown Hispanic/Latino ethnicity is a risk factor for worse survival in patients with gastric cancer linked to disparate access to care. We aimed to address whether Hispanic patients treated within safety-net hospital systems continue to experience this survival deficit compared to non-Hispanic patients.</p><p><strong>Methods: </strong>We performed a retrospective cohort study comparing survival between Hispanic and non-Hispanic patients diagnosed with gastric adenocarcinoma between January 1, 2016, and December 31, 2020, within Los Angeles County's safety-net hospital system. Gastric cancer-specific survival was compared between the two cohorts using the Kaplan-Meier estimate and Cox proportional-hazards regression model.</p><p><strong>Results: </strong>In total, 448 patients who received care from five medical centers were included; 348 (77.7%) patients self-identified as Hispanic and 100 (22.3%) as non-Hispanic. Mean follow-up time was 2.0 years (median 0.91 years, IQR, 0.34-2.5 years). Hispanic patients were found to be diagnosed at a younger age (55.6 vs. 60.7 years, P < 0.01), demonstrate higher state area deprivation index (6.4 vs. 5.0, P < 0.01), and present with metastatic disease (59.8% vs. 45%, P = 0.04). After adjusting social and oncologic variables, Hispanic ethnicity remained an independent risk factor for worse survival [HR 1.56, (95% CI, 1.06-2.28); P = 0.02].</p><p><strong>Conclusions: </strong>Hispanic patients treated within a large, multicenter safety-net hospital system experience worse survival compared to non-Hispanic patients. This suggests ethnic disparities exist within safety-net hospital systems, independent of known clinicopathologic factors.</p><p><strong>Impact: </strong>Improving outcomes for Hispanic patients with gastric cancer requires future efforts aimed at defining and addressing these unidentified barriers to care. See related In the Spotlight, p. 12.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"75-84"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Area Estimation of PSA Testing in US States and Counties.","authors":"Benmei Liu, John R Pleis, Diba Khan, Van L Parsons, Richard Lee, Bill Cai, Machell Town, Eric J Feuer, Yulei He","doi":"10.1158/1055-9965.EPI-24-1086","DOIUrl":"10.1158/1055-9965.EPI-24-1086","url":null,"abstract":"<p><strong>Background: </strong>In 2012, the US Preventive Services Task Force recommended against prostate cancer screening using the PSA test for all age groups. In 2018, the US Preventive Services Task Force's recommendation shifted from a \"D\" (not recommended) to a \"C\" (selectively offering PSA-based screening based on professional judgment and patient preferences) in men ages 55 to 69. Limited reliable county-level prostate cancer screening data are available for cancer surveillance purposes.</p><p><strong>Methods: </strong>Utilizing data from the National Health Interview Survey (NHIS) and Behavioral Risk Factor Surveillance System (BRFSS) collected in 2012 to 2019, state- and county-level small area models were developed for estimating PSA testing. Model diagnosis, internal validation, and external validation examining associations of PSA testing and prostate cancer incidence were conducted.</p><p><strong>Results: </strong>Model-based estimates of PSA testing rates were produced for all US states and 3,142 counties for two data periods: 2012 to 2016 and 2018 to 2019. Geographic variations across counties were demonstrated through maps. Moderate positive correlations between PSA-based screening and prostate cancer incidence were observed, e.g., the state-level weighted Pearson's correlation coefficients were 0.5025 (P value = 0.0002) and 0.3691 (P value = 0.0077) for 2012 to 2016 and 2018 to 2019, respectively.</p><p><strong>Conclusions: </strong>These modeled estimates showed improved precision and adjusted for the differences between the BRFSS and NHIS. The approach of combining the NHIS and BRFSS utilized strengths of the larger sample size of the BRFSS and generally higher response rates and better household coverage from the NHIS.</p><p><strong>Impact: </strong>The resulting small area estimates offer a valuable resource for the cancer surveillance community, aiding in targeted interventions, decision making, and further research endeavors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"197-204"},"PeriodicalIF":3.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}